Supplementary Materials

Supplementary Material for:

Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys

Yumei Xiong, Kenneth Walker, Xiaoshan Min, Clarence Hale, Thanhvien Tran, Renee Komorowski, Jerry Yang, Jasmine Davda, Noi Nuanmanee, Dao Kemp, Xiaozhen Wang, Hantao Liu, Silke Miller, Ki Jeong Lee, Zhulun Wang, Murielle M. Véniant*

*Corresponding author. Email: mveniant{at}amgen.com

Published 18 October 2017, Sci. Transl. Med. 9, eaan8732 (2017)
DOI: 10.1126/scitranslmed.aan8732

This PDF file includes:

  • Fig. S1. Improved metabolic parameters in AAV-hGDF15–injected ob/ob, db/db, and KKAy mice.
  • Fig. S2. Effects of rmGDF15, rhGDF15, and mGDF15 antibodies on food intake in ob/ob mice.
  • Fig. S3. Metabolic parameters in obese mice and obese cynomolgus monkeys treated with rhGDF15 protein.
  • Fig. S4. PK of GDF15 proteins.
  • Fig. S5. Model of DhCpmFc fusion protein.
  • Fig. S6. PK of long-acting GDF15 proteins.
  • Fig. S7. Reduced food intake and body weight in Zucker fatty rats treated with DhCpmFc protein.
  • Fig. S8. No delay in gastric emptying in GDF15-treated mice after vagotomy.
  • Fig. S9. Thick sections of the AP showing c-FOS–positive neurons in additional amylin and high-dose GDF15 peptide–dosed mice.
  • Fig. S10. Biodistribution of Fc immunoreactivity in jejunum, stomach, and liver.
  • Table S1. Pathology report of DIO mice 1 year after control AAV or AAVGDF15 injection.
  • Table S2. Statistics of crystallographic data and refinement.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S3. Individual subject-level data of quantitative studies (provided as an Excel file).